Association of plasminogen activator inhibitor gene polymorphism of endometrial cancer

• Main Authors: Chung-Kuang, 蘇重光
• Other Authors: 周明智
• Format: Others
• Language: zh-TW
• Published: 2012
• Online Access: http://ndltd.ncl.edu.tw/handle/68807110923285864787

博士 === 中山醫學大學 === 醫學研究所 === 100 === To investigate the association of urokinase plasminogen activator (u-PA) system genes, including u-PA, u-PA receptor (u-PAR), and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms, with risk of endometrial cancer. We enrolled a total of 134 patients with endometrial cancer confirmed by histopathology and 302 unrelated healthy individuals. Genetic polymorphisms of u-PA system genes, including u-PA rs4065 C/T SNP, u-PAR rs344781 T/C single nucleotide polymorphism (SNP) and PAI-1 rs1799889 4G/5G SNP were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) genotyping analysis. The results show that frequency of PAI-1 rs1799889 4G/4G genotype and 4G allele differed significantly between patients with endometrial cancer (36.6% and 61.6% respectively) and healthy individuals (25.5% and 52.2 % respectively). Individuals with PAI-1 rs1799889 4G/4G genotype were at higher risk of endometrial cancer (OR=2.26; 95%CI: 1.20-4.27). Stratification analysis showed individuals with PAI-1 rs1799889 4G/4G genotype were at elevated risk for endometrioid type (OR=2.49; 95% CI 1.27-4.88), low stage (stage I-II) endometrial cancer (OR=2.34; 95% CI 1.21-4.52). However, no significant differences in u-PA C/T SNP, u-PAR T/C SNP genotypes were observed between endometrial carcinoma cases and controls.